THIS DOCUMENT IS A FREE NON BINDING TRANSLATION, FOR INFORMATION PURPOSES ONLY, OF THE FRENCH LANGUAGE SUPPLEMENT DATED 13 NOVEMBER 2026 WHICH RECEIVED THE APPROVAL NUMBER 26-400 FROM THE *AUTORITE DES MARCHES FINANCIERS* ON 13 NOVEMBER 2026 (THE "SUPPLEMENT"). ONLY THE SUPPLEMENT WAS GRANTED AN APPROVAL NUMBER BY THE *AUTORITE DES MARCHES FINANCIERS*. IN THE EVENT OF ANY AMBIGUITY OR CONFLICT BETWEEN CORRESPONDING STATEMENTS OR OTHER ITEMS CONTAINED IN THE SUPPLEMENT AND THIS DOCUMENT, THE RELEVANT STATEMENTS OR OTHER ITEMS CONTAINED IN THE SUPPLEMENT SHALL PREVAIL. FOR THE AVOIDANCE OF DOUBT, REFERENCES IN THIS DOCUMENT TO THE "SUPPLEMENT" ARE TO THE "SUPPLEMENT" AND DO NOT INCLUDE ITS ENGLISH TRANSLATION.

SUPPLEMENT DATED 13 NOVEMBER 2026 TO THE BASE PROSPECTUS DATED 17 APRIL 2026

CAISSE DES DEPOTS ET CONSIGNATIONS
(an *établissement spécial* in France)
€3,000,000,000
***Titres Négociables à Moyen Terme* Admission Programme**

This second supplement (the "**Second Supplement**") which has obtained the approval number 26-400 on 13 November 2026 from the *Autorité des marchés financiers* (the "**AMF**") is supplemental to and must be read in conjunction with the base prospectus dated 17 April 2026 which was granted the approval number 26-092 on 17 April 2026 by the AMF (the "**Base Prospectus**") and the supplement dated 3 July 2026 which was granted the approval number 26-258 on 3 July 2026 by the AMF (the "**First Supplement**") prepared by Caisse des dépôts et consignations ("**Caisse des Dépôts**" or the "**Issuer**") with respect to its €3,000,000,000 *Titres Négociables à Moyen Terme* Admission Programme (the "**Programme**").

Application has been made for approval of this Second Supplement to the AMF as competent authority under the Regulation (EU) 2017/1129, as amended (the "**Prospectus Regulation**"). This Second Supplement has been prepared for the purpose of Article 23 of the Prospectus Regulation. The Base Prospectus (which includes, for the avoidance of doubt, the Fist Supplement and this Second Supplement) constitutes a base prospectus for the purposes of Article 8 of the Prospectus Regulation.

Terms defined in the Base Prospectus have the same meaning when used in this Second Supplement.

This Second Supplement modifies and completes the Base Prospectus.

Copies of this Second Supplement, together with the documents incorporated by reference herein, can be obtained free of charge from the principal office of the Issuer and will be available on the Issuer's website (www.caissedesdepots.fr) and the AMF's website (www.amf-france.org).

Save as disclosed in this Second Supplement, there has been no other significant new factor, material omission or inaccuracy relating to information included in the Base Prospectus (as supplemented by the First Supplement and this Second Supplement) which may affect the assessment of the Notes issued under the Programme since the publication of the Base Prospectus.

To the extent that there is any inconsistency between (a) any statement in this Second Supplement and (b) any other statement in or incorporated by reference in the Base Prospectus or the First Supplement, the statements in (a) above will prevail.

This Second Supplement has been prepared in order to reflect the fact that the Programme's and the Issuer's perspective in relation to its Fitch rating has been downgraded from A+ stable to A+ negative. Sections of the Base Prospectus have been updated accordingly.

Table of Contents

FRONT PAGE 4
GENERAL DESCRIPTION OF THE PROGRAMME 5
GENERAL INFORMATION 6
RESPONSIBILITY FOR THE SECOND SUPPLEMENT 7

FRONT PAGE

The first sentence of the eighth paragraph of the front page of the Base Prospectus shall be deleted and replaced by the following:

“The Programme and the Issuer are currently rated A+ with a negative outlook by Fitch Ratings Ireland Limited ("**Fitch**"), Aa3 with a negative outlook by Moody's France S.A.S. ("**Moody's**") and A+ with a stable outlook by S&P Global Ratings Europe Limited ("**S&P**").”

GENERAL DESCRIPTION OF THE PROGRAMME

The first sentence of the paragraph entitled Rating in the "General Description of the Programme" section on page 10 is deleted and replaced by the following:

> "The Programme and the Issuer are currently rated A+ with a negative outlook by Fitch Ratings Ireland Limited ("**Fitch**"), Aa3 with a negative outlook by Moody's France S.A.S. ("**Moody's**") and A+ with a stable outlook by S&P Global Ratings Europe Limited ("**S&P**")."

GENERAL INFORMATION

The first sentence of the paragraph 15 in the "General Information" section on page 96 shall be deleted and replaced by the following:

"The Programme and the Issuer are currently rated A+ with a negative outlook by Fitch Ratings Ireland Limited ("**Fitch**"), Aa3 with a negative outlook by Moody's France S.A.S. ("**Moody's**") and A+ with a stable outlook by S&P Global Ratings Europe Limited ("**S&P**")."

RESPONSIBILITY FOR THE SECOND SUPPLEMENT

Individual assuming responsibility for the Second Supplement to the Base Prospectus

In the name of the Issuer

To the best knowledge of the Issuer, the information contained in this Second Supplement is in accordance with the facts and contains no omission likely to affect its import.

Caisse des dépôts et consignations
56, rue de Lille
75007 Paris
France

Represented by Nathalie Tubiana
Directrice des finances et de la politique durable

Executed in Paris on 13 November 2026

Autorité des marchés financiers

This Second Supplement has been approved on 13 November 2026 by the AMF, in its capacity as competent authority under Regulation (EU) 2017/1129.

The AMF has approved this Second Supplement after having verified that the information it contains is complete, coherent and comprehensible within the meaning of Regulation (EU) 2017/1129. The approval does not imply the verification of the accuracy of this information by the AMF.

This approval is not a favourable opinion on the Issuer and on the quality of the Notes described in this Second Supplement. Investors should make their own assessment of the opportunity to invest in such Notes.

The approval number applicable to this Second Supplement is n°26-400.